Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Á¦ I º´±â ½Å¼¼Æ÷¾Ï¿¡ ´ëÇÑ ÀÓ»óÀû °íÂû Clinical Study of Stage I Renal Cell Carcinoma

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 6È£ p.1100 ~ 1105
¼Ò¼Ó »ó¼¼Á¤º¸
±èÈñ¿­/Heeyoul Kim ¿ì¿øÈñ/±è´ö±³/³ë¼¼°æ/À̼±ÁÖ/À强±¸/Won Hee Woo/Duk-Kyo Kim/Sei Kyung Rho/Sun-Ju Lee/Sung-Goo Chang

Abstract

¼­·Ð
½Å¼¼Æ÷¾ÏÀº ½ÅÀå¿¡ ¹ß»ýÇÏ´Â ¾Ç¼ºÁ¾¾ç Áß °¡Àå ÈçÇÏÁö¸¸, ÀüüÀûÀ¸·Î´Â ºñ±³Àû ÈçÄ¡ ¾ÊÀº
ÁúȯÀ¸·Î ¹Ì±¹ÀÇ ¿¹¿¡¼­´Â ¾î¸¥¿¡°Ô »ý±â´Â ¾ÏÀÇ ¾à 3%¸¦ Â÷ÁöÇϸç ÃÊÁø½Ã ¾à 1/3¿¡¼­ ÀÌ
¹Ì ÀüÀÌµÈ »óÅ·Π¹ß°ßµÈ´Ù. ¶ÇÇÑ ½ÅÀûÃâ¼úÈÄ È¯ÀÚÀÇ ¾à 1/3Á¤µµ¿¡¼­ ÀüÀÌ°¡ ¹ß»ýÇϸç, ÁøÇà
µÈ ½Å¼¼Æ÷¾Ï¿¡ ´ëÇؼ­´Â È­Çпä¹ý, È£¸£¸ó¿ä¹ý, ¸é¿ª¿ä¹ý, ¹æ»ç¼±¿ä¹ý µîÀÌ ½ÃµµµÇ°í ÀÖÀ¸³ª
±× È¿°ú´Â ¸Å¿ì ¹Ì¹ÌÇÑ Á¤µµÀÌ´Ù.
µû¶ó¼­ ½Å¼¼Æ÷¾ÏÀº Á¶±â¹ß°ß¿¡ µû¸¥ ±ÙÄ¡Àû ½ÅÀûÃâ¼ú¸¸ÀÌ °¡Àå È¿À²ÀûÀÎ Ä¡·á¹ýÀÌ´Ù.
½Å¼¼Æ÷¾ÏÀÇ ¿¹Èĸ¦ °áÁ¤ÇÏ´Â ÀÎÀÚ´Â º´±â, Á¾¾ç ¼¼Æ÷ ÇüÅ ¹× Á¶Á÷ÇÐÀû ºÐÈ­µµ, ¾Ï¼¼Æ÷ÀÇ
¿°»öü ¹× DNA ploidyµîÀÌ ¾Ë·ÁÁ® ¿ÔÀ¸³ª, ¼ö¼úÈÄ º´¸®Á¶Á÷ÇÐÀû º´±â°¡ °¡Àå Áß¿äÇÑ °ÍÀ¸
·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÃÖ±Ù TNM systemÀÌ Àû¿ëµÇ±â Àü±îÁö´Â ÀüÅëÀûÀ¸·Î Robson º´±â¸¦ ¸¹ÀÌ
Àû¿ëÇØ ¿Ô´Ù.
½Å¼¼Æ÷¾ÏÀº ±× ÀÓ»ó°æ°ú°¡ ¸Å¿ì ´Ù¾çÇÏ°í ¿¹ÃøÇϱ⠾î·Á¿î Ư¡ÀÌ ÀÖ´Ù.
ÈçÈ÷ Robson stage I ÀÎ ½Å¼¼Æ÷¾ÏÀÇ °æ¿ì ±ÙÄ¡Àû ½ÅÀûÃâ¼úÈÄ ¸Å¿ì ÁÁÀº ¿¹Èĸ¦ °®´Â °Í
À¸·Î ¾Ë·ÁÁ® ¿ÔÀ¸³ª ÀÌ¿¡ ´ëÇÑ ±¸Ã¼Àû ºÐ¼®Àº ¹ÌÈíÇÑ ÆíÀÌ´Ù.
ÀúÀÚµéÀº ±ÙÄ¡Àû ½ÅÀûÃâ¼úÈÄ º´¸® Á¶Á÷ÇÐÀûÀ¸·Î Á¦ I º´±â ½Å¼¼Æ÷¾ÏÀ¸·Î Áø´Ü ¹ÞÀº ȯÀÚ
¿¡ À־ ±× ¿¹ÈÄ¿Í ±× °áÁ¤ ÀÎÀÚ¿¡ ´ëÇØ Á¶»çÇÏ¿© ½ÇÁ¦·Î Á¦ I º´±â ½Å¼¼Æ÷¾ÏÀº ¼úÈÄ ¾ç
È£ÇÑ ¿¹Èĸ¦ º¸ÀÌ´ÂÁö? ¶Ç´Â ¿¹ÈÄ¿¡ ¿µÇâÀ» ÁÖ´Â ¿äÀÎÀÌ ÀÖ´Ù¸é ±×°ÍÀº ¾î¶°ÇÑ ¿ä¼ÒÀÎÁö¸¦
ÈÄÇâÀûÀ¸·Î Á¶»çÇÏ¿© ±ÙÄ¡Àû ½ÅÀûÃâ¼úÈÄ º´¸®Á¶Á÷ÇÐÀûÀ¸·Î Á¦ I º´±â ½Å¼¼Æ÷¾ÏÀ¸·Î Áø´Ü ¹Þ
Àº ȯÀÚµéÀÇ ¼úÈÄ ÃßÀûÁ¶»çÀÇ ÁÖ¾ÈÁ¡°ú ¿¹ÈÄ ÆÇÁ¤ÀÇ ¿¹Ãø ÁöÇ¥¸¦ ¼³Á¤ÇÏ°íÀÚ º» ¿¬±¸¸¦ ½Ç
½ÃÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : This study was attempted to investigate the prognostic factors for the
outcome of stage I renal cell carcinoma after radical nephrectomy.
Materials and Methods: Twenty nine patients treated from 1984 to 1995 at Kyung Hee
University Medical Center were studied retrospectively. All of them were diagnosed with
pathologic Robson stage I renal cell carcinoma after radical nephrectomy.
Results : Males were affected three times more frequently than females. The tumor
was detected on the right kidney in 15 cases, and on the left in 14. Average follow up
period was 36.6 months, average disease free interval was 29.4 months and median
survival was 30 months. During the follow up, 9 patients(31.0%) expired due to liver
and lung metastasis at postoperate 21.6 months on average. Eleven patients(37.9%)
developed distant metastasis in the follow up. There was no local recurrence of tumor,
Seventeen patients were diagnosed incidentally without clinical symptoms. In our
retrospective study for stage I renal cell carcinoma, there were no predictive prognostic
parameters for predicting the outcome of patients, except for the incidental diagnosis of
the tumor.
Conclusions : These results suggest that incidental diagnosis of the tumor may be the
most important prognostic factor for the outcome of stage I renal cell carcinoma.
Although the patients were confirmed as stage I renal cell carcinoma pathologically after
radical nephrectomy, close follow up is very important, because of high incidence of
metastasis. We recommand that chest X-ray, abdominal ultrasonogram and bone scan
should be checked at 3 months interval for postoperative one year even though stage I
renal cell carcinoma.

Å°¿öµå

Stage I renal cell carcinoma; Radical nephrectomy; Metastasis; Early diagnosis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS